- Home
- STCN vs CUE Comparison
STCN vs CUE Comparison
Compare STCN & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STCN
- CUE
- Stock Information
- Founded
- STCN 1986
- CUE 2014
- Country
- STCN United States
- CUE United States
- Employees
- STCN N/A
- CUE N/A
- Industry
- STCN Advertising
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- STCN Consumer Discretionary
- CUE Health Care
- Exchange
- STCN Nasdaq
- CUE Nasdaq
- Market Cap
- STCN 63.4M
- CUE 64.4M
- IPO Year
- STCN 1994
- CUE 2018
- Fundamental
- Price
- STCN $9.80
- CUE $1.50
- Analyst Decision
- STCN
- CUE Strong Buy
- Analyst Count
- STCN 0
- CUE 5
- Target Price
- STCN N/A
- CUE $5.00
- AVG Volume (30 Days)
- STCN 30.8K
- CUE 923.5K
- Earning Date
- STCN 12-12-2024
- CUE 11-19-2024
- Dividend Yield
- STCN N/A
- CUE N/A
- EPS Growth
- STCN 203.29
- CUE N/A
- EPS
- STCN 3.11
- CUE N/A
- Revenue
- STCN $174,109,000.00
- CUE $8,295,000.00
- Revenue This Year
- STCN N/A
- CUE $104.81
- Revenue Next Year
- STCN N/A
- CUE N/A
- P/E Ratio
- STCN $3.27
- CUE N/A
- Revenue Growth
- STCN N/A
- CUE 363.67
- 52 Week Low
- STCN $7.36
- CUE $0.45
- 52 Week High
- STCN $13.00
- CUE $3.25
- Technical
- Relative Strength Index (RSI)
- STCN 40.83
- CUE 50.94
- Support Level
- STCN $9.66
- CUE $1.32
- Resistance Level
- STCN $10.32
- CUE $1.99
- Average True Range (ATR)
- STCN 0.61
- CUE 0.29
- MACD
- STCN -0.02
- CUE -0.04
- Stochastic Oscillator
- STCN 8.81
- CUE 26.58
About STCN Steel Connect Inc.
Steel Connect Inc is a diversified holding company. The company's operating segment include Direct Marketing and Supply Chain. It generates maximum revenue from the Direct Marketing segment. Geographically, it derives a majority of revenue from the United States and also has a presence in China; Netherlands, and others. The company serves clients in various industries including consumer electronics, communications, computing, software, storage, and retail industries.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.